We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome.
- Authors
Davids, M. S.; Rogers, K. A.; Jain, N.; Tyekucheva, S.; Ren, Y.; Carey, C.; Montegaard, J.; Hajdenberg, M.; Ryan, C. E.; Merryman, R.; Kim, A.; Crombie, J.; Jacobson, C. A.; LaCasce, A. S.; Fisher, D. C.; Ahn, I. E.; Parry, E. M.; Brown, J. R.; Thompson, P. A.
- Abstract
B Introduction: b We previously reported promising efficacy for venetoclax (V) plus da-R-EPOCH (VR-EPOCH) for 26 patients (pts) with CLL who developed Richter Syndrome (RS), with a CR rate of 50% and median OS of 19.6 mo.; however, hematologic and infectious complications were common (Davids et al., Blood, 2022). Median # prior CLL treatments was 1 (range 1-9), including 44% post-BTKi and 17% post-V; 4 pts (15%) had prior treatment for RS. 8 pts with initial CLL marrow involvement had re-staging marrows, and 88% (7/8) were uMRD for CLL by flow at 10-4. 7 pts in remission electively went to alloHCT.
- Subjects
RICHTER syndrome; VENETOCLAX; ANTINEOPLASTIC combined chemotherapy protocols; MEDICAL education; CHRONIC lymphocytic leukemia
- Publication
Hematological Oncology, 2023, Vol 41, p466
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_343